阿达木单抗无应答或按设计转换至巴瑞替尼的类风湿关节炎III期临床结局
基于III期RA-BEAM及长期延伸研究,评估因无应答或研究设计从阿达木单抗转换至巴瑞替尼4 mg的类风湿关节炎患者结局。转换后12周内疾病控制、躯体功能和疼痛均有改善,且治疗中出现的不良事件、严重不良事件和感染未见增加。
要点
- 阿达木单抗转换至巴瑞替尼无需洗脱期,转换后12周内疾病控制、功能和疼痛改善。
- 转换患者与继续巴瑞替尼者的TEAE、严重事件及感染暴露调整发生率相似。
- RA-BEAM中巴瑞替尼组7%、阿达木单抗组12%患者被补救为巴瑞替尼。
核心结论
- 从阿达木单抗转换至巴瑞替尼(无洗脱期)与转换后初始12周内疾病控制、躯体功能和疼痛改善相关,且未增加TEAE、严重不良事件或感染。
研究设计与样本
- III期RA-BEAM研究将患者按3:3:2随机分配至安慰剂、巴瑞替尼4 mg每日一次或阿达木单抗40 mg每两周一次。
- 第16周或后续访视时无应答者被补救为开放标签巴瑞替尼4 mg;第52周可进入长期延伸研究并继续巴瑞替尼或从阿达木单抗转换至巴瑞替尼4 mg,无阿达木单抗洗脱期。
- 评估达到低疾病活动度和缓解的患者百分比,以及躯体功能、患者疼痛评估和安全性。
主要发现
- RA-BEAM中35例(7%)巴瑞替尼治疗和40例(12%)阿达木单抗治疗患者被补救为巴瑞替尼。
- RA-BEAM中未补救的巴瑞替尼组78%(381/487)和阿达木单抗组72%(238/330)患者进入长期延伸研究并继续或转换至巴瑞替尼。
- 巴瑞替尼补救和阿达木单抗补救患者中,补救后12周内所有指标较补救时均有显著改善。
- 从阿达木单抗转换至巴瑞替尼的患者在长期延伸研究12周内疾病控制改善。
- 转换至巴瑞替尼者与继续巴瑞替尼者的TEAE和感染(包括严重事件)暴露调整发生率相似。
关键数值与推荐
- RA-BEAM随机比例:安慰剂:巴瑞替尼4 mg:阿达木单抗40 mg为3:3:2。
- 补救剂量为开放标签巴瑞替尼4 mg;转换至巴瑞替尼4 mg无阿达木单抗洗脱期。
- RA-BEAM补救率:巴瑞替尼组7%(35例),阿达木单抗组12%(40例)。
- 进入长期延伸研究比例:巴瑞替尼组78%(381/487),阿达木单抗组72%(238/330)。
临床怎么用
- 对阿达木单抗无应答的类风湿关节炎患者,可直接转换至巴瑞替尼4 mg而无需阿达木单抗洗脱期。
- 转换后应关注初始12周内疾病控制、躯体功能和疼痛的改善评估,并监测TEAE和感染。
局限性
- 原文未报告转换患者的具体样本量、置信区间和P值。
- 原文未报告长期延伸研究中转换后超过12周的疗效数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate clinical outcomes in patients who changed treatment from adalimumab to baricitinib, an oral Janus kinase (JAK)1/JAK2 inhibitor, during a phase III programme. METHODS: In phase III RA-BEAM, patients were randomised 3:3:2 to placebo, baricitinib 4 mg once daily, or adalimumab 40 mg biweekly. At week 16 or subsequent visits, non-responders were rescued to open-label baricitinib 4 mg. At week 52, patients could enter a long-term extension (LTE) and continue on baricitinib or switch from adalimumab to baricitinib 4 mg with no adalimumab washout period. Percentage of patients achieving low disease activity and remission were assessed, along with physical function, patient's assessment of pain, and safety. RESULTS: Thirty-five (7%) baricitinib-treated and 40 (12%) adalimumab-treated patients were rescued to baricitinib in RA-BEAM; 78% (381/487) of baricitinib-treated and 72% (238/330) of adalimumab-treated patients who were not rescued in RA-BEAM, entered the LTE and continued/were switched to baricitinib. In both baricitinib-rescued and adalimumab-rescued patients, there were significant improvements in all measures up to 12 weeks after rescue compared with the time of rescue. Patients who switched from adalimumab to baricitinib showed improvements in disease control through 12 weeks in the LTE. Exposure-adjusted incidence rates for treatment-emergent adverse events (TEAEs) and infections, including serious events, were similar for patients who switched from adalimumab to baricitinib and those who continued on baricitinib. CONCLUSIONS: Switching from adalimumab to baricitinib (without adalimumab washout) was associated with improvements in disease control, physical function and pain during the initial 12 weeks postswitch, without an increase in TEAEs, serious adverse events or infections. TRIAL REGISTRATION NUMBERS: NCT01710358, NCT01885078.
引用
- Tanaka Y, Fautrel B, Keystone EC, et al. Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis. Ann Rheum Dis. 2019. PMID: 31040122. doi:10.1136/annrheumdis-2018-214529
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。